MEDIA RELEASE

Contact: Laura Shannon, Communications Manager, CTTI, laura.shannon@duke.edu

CTTI and FDA Convene Workshop on Including Patient Perspectives in Clinical Trials

The public workshop will explore best practices for incorporating patient input on clinical trial access, design, conduct, and follow-up

Durham, N.C.—Jan. 28, 2019—The Clinical Trials Transformation Initiative (CTTI) will convene a public workshop, “Enhancing the Incorporation of Patient Perspectives in Clinical Trials,” in collaboration with the U.S. Food and Drug Administration (FDA) on Mon., March 18, from 9:00 a.m. to 5:00 p.m. at the Tommy Douglas Conference Center in Silver Spring, Md.

“We know that patients and patient advocates play a key role in making trials more efficient, effective, and patient-centered,” said Pamela Tenaerts, executive director of CTTI. “This is an excellent opportunity for patients, investigators, and other groups to have their voices heard and, ultimately, help shape better clinical trials.”

The workshop will gather input from patients, caregivers, industry, academic researchers, and expert practitioners on the challenges and barriers to patient participation in clinical trials. It will also seek ideas for best practices and key considerations for enhancing the incorporation of patient perspectives on clinical trial access, design, conduct, and post-trial follow-up.

This workshop meets an FDA commitment that is part of the sixth authorization of the Prescription Drug User Fee Act (PDUFA VI). A published report on proceedings and recommendations from the workshop will be made publicly available.

Register online to attend the workshop—registration is free and based on space availability, with priority given to early registrants. A live webcast will also be available.

About the Clinical Trials Transformation Initiative (CTTI)

The Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by Duke University and the U.S. Food and Drug Administration, seeks to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials. Comprised of more than 80 member organizations—representing academia, clinical investigators, government and regulatory agencies, industry, institutional review boards, patient advocacy groups, and other groups—CTTI is transforming the clinical trials landscape by developing evidence-based solutions to clinical research challenges. Many
regulatory agencies and organizations have applied CTTI's more than 20 existing recommendations, and associated resources, to make better clinical trials a reality. Learn more about CTTI projects, recommendations, and resources at www.ctti-clinicaltrials.org.

###